Table 4 Immunophenotype of primary and... | American Society of Hematology

Table 4

Immunophenotype of primary and secondary AMLs

BM	Cell Type	Control*	1° 1586†	2° 6753‡	1° 4525	2° 6755	2° 6756	2° 6757
Marker
Gr1⁺ CD11b⁺	Granulocyte/monocyte	1.5 ± 7.9	50	27	0.5	0	0.5	1
F4/80⁺ CD11b⁺	Macrophage	2.3 ± 0.9	82	58	0.8	0	0.3	0.4
Kit⁺ Gr1⁻	Immature	1.3 ± 0.3	5	37	98	99	94	90
CD19⁺ IgM⁻	Immature B lymphoid	1.2 ± 0.4	0.5	0.4	96	97	94	96
CD19⁺ IgM⁺	Mature B lymphoid	4.5 ± 1.5	0.4	0.5	1	1.3	1.1	0.5
CD4⁺	T lymphoid	2.8 ± 0.8	1	2.0	1.5	1.6	1.6	1.7
CD8⁺	T lymphoid	0.5 ± 0.2	0.2	1.0	0.2	0.2	0.1	0.1
CD71⁺ Ter119⁺	Erythroid	48 ± 5	1.5	0.9	0.3	0	0.3	0.4
Spleen
Gr1⁺ CD11b⁺	Granulocyte/monocyte	7 ± 2.6	29	6.0	1	0	0.4	0.5
F4/80⁺ CD11b⁺	Macrophage	5.3 ± 1.2	60	16	7	1.0	0.5	1
Kit⁺ Gr1⁻	Immature	1.3 ± 0.3	20	67	82	98	89	88
CD19⁺ IgM⁻	Immature B lymphoid	2.3 ± 1.3	1	0.6	75	96	69	69
CD19⁺ IgM⁺	Mature B lymphoid	12.7 ± 6.2	2	0.6	5	2.0	5	6
CD4⁺	T lymphoid	6 ± 1.7	2	1.2	7	1.1	2.3	2.8
CD8⁺	T lymphoid	1.3 ± 0.6	0.2	0.5	2	0.9	0.4	1
CD71⁺ Ter119⁺	Erythroid	54.3 ± 4.1	6	6.3	4	1	0.5	0.5

BM	Cell Type	Control*	1° 1586†	2° 6753‡	1° 4525	2° 6755	2° 6756	2° 6757
Marker
Gr1⁺ CD11b⁺	Granulocyte/monocyte	1.5 ± 7.9	50	27	0.5	0	0.5	1
F4/80⁺ CD11b⁺	Macrophage	2.3 ± 0.9	82	58	0.8	0	0.3	0.4
Kit⁺ Gr1⁻	Immature	1.3 ± 0.3	5	37	98	99	94	90
CD19⁺ IgM⁻	Immature B lymphoid	1.2 ± 0.4	0.5	0.4	96	97	94	96
CD19⁺ IgM⁺	Mature B lymphoid	4.5 ± 1.5	0.4	0.5	1	1.3	1.1	0.5
CD4⁺	T lymphoid	2.8 ± 0.8	1	2.0	1.5	1.6	1.6	1.7
CD8⁺	T lymphoid	0.5 ± 0.2	0.2	1.0	0.2	0.2	0.1	0.1
CD71⁺ Ter119⁺	Erythroid	48 ± 5	1.5	0.9	0.3	0	0.3	0.4
Spleen
Gr1⁺ CD11b⁺	Granulocyte/monocyte	7 ± 2.6	29	6.0	1	0	0.4	0.5
F4/80⁺ CD11b⁺	Macrophage	5.3 ± 1.2	60	16	7	1.0	0.5	1
Kit⁺ Gr1⁻	Immature	1.3 ± 0.3	20	67	82	98	89	88
CD19⁺ IgM⁻	Immature B lymphoid	2.3 ± 1.3	1	0.6	75	96	69	69
CD19⁺ IgM⁺	Mature B lymphoid	12.7 ± 6.2	2	0.6	5	2.0	5	6
CD4⁺	T lymphoid	6 ± 1.7	2	1.2	7	1.1	2.3	2.8
CD8⁺	T lymphoid	1.3 ± 0.6	0.2	0.5	2	0.9	0.4	1
CD71⁺ Ter119⁺	Erythroid	54.3 ± 4.1	6	6.3	4	1	0.5	0.5

Control values determined from 3 mice transplanted with Egr1^+/−, Apc^del/+ BM transduced with control Luc shRNA. The mice were euthanized between 290 to 300 days as a control.

†

1° is the primary mouse with AML.

‡

2° is the secondary transplant. These mice were transplanted with leukemia cells from primary mice with AML.

View Large

This Feature Is Available To Subscribers Only